Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.
- DOI
- 10.1016/j.clml.2026.03.016
- Published
- 2026 Jun
- Container
- Clinical lymphoma, myeloma & leukemia
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.clml.2026.03.016,
title = {Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.},
author = {Hamadeh IS and Merz M and Derkach A and Modelevsky L and Lesokhin AM and Mailankody S and Hultcrantz ML and Tan CR and Hassoun H and Shah UA and Maclachlan K and Rajeeve S and Hashmi H and Maura F and Firestone RS and Wang AX and Amin A and Patel D and Scordo M and Shah GL and Landau HJ and Giralt S and Usmani SZ and Korde N},
year = {2026},
journal = {Clinical lymphoma, myeloma \& leukemia},
doi = {10.1016/j.clml.2026.03.016},
url = {https://doi.org/10.1016/j.clml.2026.03.016}
}RIS
TY - JOUR TI - Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies. AU - Hamadeh IS AU - Merz M AU - Derkach A AU - Modelevsky L AU - Lesokhin AM AU - Mailankody S AU - Hultcrantz ML AU - Tan CR AU - Hassoun H AU - Shah UA AU - Maclachlan K AU - Rajeeve S AU - Hashmi H AU - Maura F AU - Firestone RS AU - Wang AX AU - Amin A AU - Patel D AU - Scordo M AU - Shah GL AU - Landau HJ AU - Giralt S AU - Usmani SZ AU - Korde N PY - 2026 JO - Clinical lymphoma, myeloma & leukemia DO - 10.1016/j.clml.2026.03.016 UR - https://doi.org/10.1016/j.clml.2026.03.016 ER -
APA
IS, H., M, M., A, D., L, M., AM, L., S, M., ML, H., CR, T., H, H., UA, S., K, M., S, R., H, H., F, M., RS, F., AX, W., A, A., D, P., M, S., GL, S., HJ, L., S, G., SZ, U., & N, K. (2026). Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.. Clinical lymphoma, myeloma & leukemia. https://doi.org/10.1016/j.clml.2026.03.016
Source records
- pubmed · retrieved 2026-09-27T17:22:55.276Z
- europe-pmc · retrieved 2026-09-27T17:22:55.291Z